effect of Melissa officinalis in treatment of patient with Rheumatoid arthritis

INTERVENTION: Intervention 1: Melissa officinalis is a perennial herbaceous plant in the mint family (Lamiaceae). Scientific research of this plant shows that it has anti‐inflammatory, analgesic, and anti‐depressant effects. Dried M. officinalis leaves after powdering in the mill, were administered to patients as 500 mg capsules twice a day (once every 12 hours) for 8 weeks. Intervention 2: Control group: Ready bread crumbs without any additives, were administered to patients as 500 mg capsules twice a day (once every 12 hours) for 8 weeks. CONDITION: M06.9 Rheumatoid arthritis disease. ; Rheumatoid arthritis, unspecified PRIMARY OUTCOME: ?Evaluation of visual analog scale (VAS). Timepoint: 2 months after and before treatment. Method of measurement: Questionnaire. Assay of Interleukin 17 (IL‐17). Timepoint: 2 months after and before treatment. Method of measurement: ELISA method. Assay of TNF‐a (Tumor necrosis factor a). Timepoint: 2 months after and before treatment. Method of measurement: ELISA method. Evaluation of Anti ccp (Cyclic Citrirullinated Peptide). Timepoint: Before treatment. Method of measurement: ELISA method. Evaluation of CRP (C‐Reactive Protein). Timepoint: 2 months after and before treatment. Method of measurement: Quantitative method with diagnostic kit. Evaluation of Disease Activity Score 28 (DAS 28). Timepoint: 2 months after and before treatment. Method of measurement: DAS Calculator software. Evaluation of ESR (Erythrocyte Sedimentation Rate. Timepoint: 2 months after and before treatment. Method of measurement: Using Westergren method. Evaluation of Rheumatoid Factor (RF). Timepoint: 2 months after and before treatment. Method of measurement: Quantitative method with diagnostic kit. SECONDARY OUTCOME: Evaluation of Beck Depression Inventory (BDI‐II). Timepoint: 2 months after and before treatment. Method of measurement: Questionnaire. Evaluation of World Health Organization Quality of Life‐BREF (WHOQOL‐BREF). Timepoint: 2 months after and before treatment. Method of measurement: Questionnaire. INCLUSION CRITERIA: Patient satisfaction and signing of informed consent form Diagnosis of patients with moderate Rheumatoid Arthritis Using the Criteria of the American College of Rheumatology Patients over 18 years During the period of the disease up to 15 years DAS Score between 3‐5